

Evidence-Based Clinical Guidelines for Chronic Diarrhea 2023.

Title: Evidence-Based Clinical Guidelines for Chronic Diarrhea 2023.

Publication year: 2024

Journal: Digestion

Authors: Guidelines Committee for Creating and Evaluating the "Evidence-Based Clinical Guidelines for Chronic Diarrhea 2023", The Japanese Gastroenterological Association, Bunkyo-ku, Japan.

Society: The Japanese Gastroenterological Association

Origin country: Japan

Target countries: Japan

DOI: 10.1159/000541121

PMID: 39197422

Source: <https://pubmed.ncbi.nlm.nih.gov/39197422/>

pmc Digestion Digestion 2985 kargersd 0150472 DIG Digestion 0012-2823 1421-9867
pmc-is-collection-domain yes pmc-collection-title Karger Author's Choice PMC11633876
PMC11633876.1 11633876 11633876 39197422 10.1159/000541121 541121 1 Guidelines
Evidence-Based Clinical Guidelines for Chronic Diarrhea 2023 JGA Diarrhea Guidelines 2753670
Ihara Eikichi a b 2753671 Manabe Noriaki a 2753672 Ohkubo Hidenori a 2753673 Ogasawara
Naotaka a 2753674 Ogino Haruei a 2753675 Kakimoto Kazuki a 2753676 Kanazawa Motoyori a
2753677 Kawahara Hidejiro a 2753678 Kusano Chika a 2753679 Kuribayashi Shiko a 2753680
Sawada Akinari a 2753681 Takagi Tomohisa a 2753682 Takano Shota a 2753683 Tomita
Toshihiko a 2753684 Noake Toshihiro a 2753685 Hojo Mariko a 2753686 Hokari Ryota a 2753687
Masaoka Tatsuhiro a 2753688 Machida Tomohiko a 2753689 Misawa Noboru a 2753690 Mishima
Yoshiyuki a 2753691 Yajima Hiroshi a 2753692 Yamamoto Sayuri a 2753693 Yamawaki Hiroshi a
2753694 Abe Tatsuya a 2753695 Araki Yasumi a 2753696 Kasugai Kunio a 2753697 Kamiya
Takeshi a 2753698 Torii Akira a 2753699 Nakajima Atsushi a 2753700 Nakada Koji a 2753701
Fukudo Shin a 2753702 Fujiwara Yasuhiro a 2753703 Miwa Hiroto a 2753704 Kataoka Hiromi a
2753705 Nagahara Akihito a 2753706 Higuchi Kazuhide a a Guidelines Committee for Creating
and Evaluating the "Evidence-Based Clinical Guidelines for Chronic Diarrhea 2023", The Japanese
Gastroenterological Association, Bunkyo-ku , Japan b Department of Medicine and Bioregulatory
Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka , Japan
Correspondence to: Eikichi Ihara, ihara.eikichi.167@m.kyushu-u.ac.jp 28 8 2024 12 2024 105 6
476864 480 497 21 6 2024 22 8 2024 2024 28 08 2024 12 12 2024 17 03 2026 © 2024 The
Author(s). Published by S. Karger AG, Basel 2024 <https://creativecommons.org/licenses/by-nc/4.0/>
This article is licensed under the Creative Commons Attribution-NonCommercial 4.0 International
License (CC BY-NC) (<http://www.karger.com/Services/OpenAccessLicense>). Usage and
distribution for commercial purposes requires written permission. Abstract The Japan
Gastroenterological Association (JGA) published the first version of clinical guidelines for chronic
diarrhea 2023. These guidelines describe the definition, classification, diagnostic criteria, diagnostic
testing methods, epidemiology, pathophysiology, and treatment of chronic diarrhea, and provide
flowcharts for the diagnosis and treatment of chronic diarrhea based on the latest evidence.
Treatment for chronic diarrhea begins by distinguishing secondary chronic constipation with a clear
etiology, such as drug-induced diarrhea, food-induced diarrhea, systemic disease-associated
diarrhea, infection-associated diarrhea, organic disease-associated diarrhea, and bile acid diarrhea.
The first line of treatment for chronic diarrhea in the narrow sense, defined in these guidelines as
functional diarrhea in routine medical care, is lifestyle modification and dietary therapy. The first
medicines to be considered for oral treatment are probiotics for regulating the gut microbiome and
anti-diarrheals. Other medications, such as 5HT₃ receptor antagonists, anticholinergics, Kampo
medicine, psychotherapy, antibiotics, bulking agents, adrenergic agonists, and somatostatin
analogs, lack sufficient evidence for their use, highlighting a challenge for future research. This
Clinical Guidelines for Chronic Diarrhea 2023, which provides the best clinical strategies for treating

chronic diarrhea in Japan, will also be useful for medical treatment worldwide.

pmc-status-qastatus 0 pmc-status-live yes pmc-status-embargo no pmc-status-released yes
pmc-prop-open-access yes pmc-prop-olp no pmc-prop-manuscript no pmc-prop-legally-suppressed
no pmc-prop-has-pdf no pmc-prop-has-supplement no pmc-prop-pdf-only no
pmc-prop-suppress-copyright no pmc-prop-is-real-version no pmc-prop-is-scanned-article no
pmc-prop-preprint no pmc-prop-in-epmc yes pmc-license-ref CC BY-NC Introduction Diarrhea is
one of the most common gastrointestinal symptoms encountered in everyday clinical practice. As
distinguished from acute diarrhea caused by infectious diseases, chronic diarrhea has a high
prevalence of approximately 5% [1 , 2] and significantly reduces quality of life. Despite its
prevalence, Japan lacked clear clinical guidelines for chronic diarrhea. In response, the Japan
Gastroenterological Association (JGA) decided to create the clinical guidelines for chronic diarrhea
in January 2021. We present the first version of JGA evidence-based clinical guidelines for chronic
diarrhea 2023. The guidelines were positively evaluated using the Appraisal of Guidelines for
Research and Evaluation II (AGREE II) tool [3]. The ratings of each domain are as follow: 58% for
domain 1 (Scope and Purpose), 43% for domain 2 (Stakeholder Involvement), 47% for domain 3
(Rigor of Development), 60% for domain 4 (Clarity of Presentation), 42% for domain 5
(Applicability), and 58% for domain 6 (Editorial Independence). The overall rating is 54%.

These guidelines primarily aim to provide information that aids in decision-making regarding
treatment policies and to improve the quality of life for patients with the common disease of chronic
diarrhea. Accordingly, these guidelines organize and interpret currently available evidence and
provide recommendations for making appropriate clinical decisions based on patient values.
Furthermore, the guidelines are intended to help patients, their families, and medical professionals
other than doctors involved in treating chronic diarrhea understand the outline of treatment for
chronic diarrhea. In sharing the information in these guidelines, our goal was to provide a resource
to help promote mutual understanding between medical professionals, patients, and their families in
treating chronic diarrhea. According to decisions from the Guideline Development Committee,
clinical questions were classified as follows. Background Question (BQ): for issues about which the
conclusion is already clear and which past guidelines are in 100% agreement.

Clinical Question (CQ): major clinical issues. Questions that can determine recommendations and
evidence-based standards through comprehensive literature searches and that influence the
direction of medical treatment.

Future Research Question (FRQ): issues for which recommendations and evidence levels cannot
be determined through a comprehensive literature search (sufficient evidence is not available for
future research topics).

Questions established for these guidelines were 27: 10 CQ, 15 FRQ, and 2 BQ. The completed
questions were categorized as follows: four addressed definition, classification, and diagnostic
criteria (2 CQ, 1 FRQ, 1 BQ); five addressed diagnostic tests (3 CQ, 1 FRQ, 5 BQ); three
addressed epidemiology (2 CQ, 1 FRQ); four addressed pathophysiology (1 CQ, 3 FRQ); and 11
addressed medical treatment (2 CQ, 9 FRQ).

An evidence search was performed using a systematic method described in a previous report [4].
In short, we searched the PubMed electronic database for articles published in English from
January 1983 to September 2021 and the Igaku Chuo Zasshi (ICHUSHI) database for articles
published in Japanese. The evidence selection criteria were as follows: initial assessment A:
systematic review, meta-analysis, or randomized controlled trial (RCT); initial assessment C: cohort
study, or case-control study; initial assessment D: case series, case report, and expert opinion.
Multiple articles were collected from the literature, and their evidence levels were ranked based on
bias risk and specific strengths. Quality of evidence was evaluated as: A for high-quality evidence,
B for moderate-quality evidence, C for low-quality evidence, and D for very low-quality evidence.
Then, the strength of the recommendations was determined using the Grading of
Recommendations Assessment, Development, and Evaluation (GRADE) system [5 , 6]. The

strength of the recommendation was evaluated on four items: (1) certainty (strength) of evidence, (2) patient wishes, (3) benefit and harm, and (4) cost evaluation. Consensus was formed by voting using a modified Delphi method, and decisions were made with 70% or more approval. If a conclusion could not be reached in the first round, the results were made public, and the voting was repeated after discussions considering the state of Japanese medicine. We determined recommendation strength as either a strong recommendation or an objection, or a weak recommendation or an objection, and created evidence-based statements and explanations for each CQ. After the final draft of the guidelines was evaluated by the guideline Evaluation Committee and modified, it was disclosed to the members of JGA, the Japanese Society of Gastroenterology, Japan Gastroenterological Endoscopy Society, and the Japan Society of Coloproctology. Furthermore, through discussions and public comments, these guidelines were completed. Adherence to the guideline will be monitored through the surveys conducted among healthcare providers by the Japanese Gastroenterological Association (JGA). Additionally, feedback on the usability and implementation of the guideline will be collected during core symposiums at the annual meetings held by the JGA. Regular clinical audits will be conducted under the supervision of the JGA. The guideline will be updated periodically based on the latest research findings and user feedback. The next update will be overseen by the JGA. Unfortunately, the patients' views and preferences could not be considered in this guideline development due to the absence of appropriate patient advocacy groups at present. Chronic diarrhea is a common disease but not a rare disease.

CQ1-1. How is diarrhea defined? Furthermore, how is chronic diarrhea defined?

Diarrhea is defined as "a condition in which the stool form is soft or watery and the frequency of defecation increases." Chronic diarrhea is defined as "a condition in which diarrhea that persists or recurs for 4 weeks or more causes various problems in daily life."

Comment : The condition of diarrhea is defined as "a condition in which the stool form is soft or watery and the frequency of defecation increases," and chronic diarrhea is defined as "a condition in which diarrhea that persists or recurs for 4 weeks or more causes various problems in daily life" [1 , 7 – 11] The Bristol Stool Form Scale (BSFS) evaluates stool form [8]. A normal defecation frequency is between 3 times per week and 2 to 3 times per day [12], whereas diarrhea is defined as an increased defecation frequency of 3 or more times per day [9 , 11]. Moreover, the chronic period is defined as 4 weeks or more because intestinal infections, the most common cause of acute diarrhea, typically resolve in 1 week or 4 weeks at the most [1]. However, the disease chronic diarrhea is a condition where diarrhea persists or recurs for 4 weeks or more, causing symptoms such as frequent bowel movements, feelings of defecation urgency, fecal incontinence, and abdominal pain [11], which interfere with activities of daily life, such as schoolwork, employment, and sleep, and requires examination, diet/lifestyle guidance, or drug treatment. These guidelines used an expanded interpretation of functional diarrhea in line with routine clinical practice to define chronic diarrhea in the "narrow sense." These diagnostic criteria are based on functional diarrhea as defined in Rome IV [13]. However, the Rome IV criteria's definition of chronic as "a condition that started more than 6 months ago and has met the respective criteria for the past 3 months" is not necessarily suitable for daily clinical practice, so it was set at 4 weeks or more for daily clinical practice. Furthermore, functional diarrhea and diarrhea-predominant irritable bowel syndrome (diarrhea-predominant IBS) are considered to be on a continuum of diseases, so considering the diversity of daily clinical practice, if chronic diarrhea is the cardinal symptom, it was decided not to inquire about accompanying symptoms such as abdominal pain.

CQ1-2. How is chronic diarrhea classified?

Chronic diarrhea is classified into eight categories: (1) drug-induced diarrhea, (2) food-induced diarrhea, (3) systemic disease-associated diarrhea, (4) infection-associated diarrhea, (5) organic disease-associated diarrhea (inflammatory or neoplastic), (6) bile acid diarrhea, (7) functional diarrhea, (8) diarrhea-dominant IBS.

Comment : Classification of chronic diarrhea is based on stool characteristics, pathophysiology, and etiology. Although distinguishing between watery, fatty, bloody, and purulent diarrhea is important for classification based on stool characteristics [14 , 15], the reality is that it is difficult for nonspecialists to grasp the overall picture because classification cannot be performed without a stool test. The American Gastroenterological Association (AGA) guidelines categorize diarrhea into drug-induced, food-induced, systemic disease-associated, infection-associated, and functional diarrhea/diarrhea-dominant IBS (IBS-D) [1] and list blood tests, physiological tests, stool tests, culture tests, imaging tests, and other methods for distinguishing between systemic disease-associated, infection-associated, organic disease-associated (inflammatory bowel disease, celiac disease, neoplastic disease, etc.), and bile acidic diarrhea [16 – 18]. Bile acidic diarrhea is further classified into three types [19]. Bile acid diarrhea is diagnosed with abnormal selenium-75-homocholic acid taurine (⁷⁵SeHCAT) scan, increased serum 7 α -hydroxy-4-cholesten-3-one (C4), and/or decreased serum fibroblast growth factor 19 (FGF-19), which positive response to administration of bile acids sequestrants (e.g., cholestyramine or colesevelam) are often substituted for, depending on the countries [19]. Careful diagnosis and interviews are important because many older people are taking drugs that contribute to diarrhea. It should also be noted that fecal incontinence is also important for differential diagnoses.

BQ1-1. What are the diagnostic criteria for chronic diarrhea?

The diagnostic criterion for chronic diarrhea is “a condition in which loose or watery stools persist or recur for 4 weeks or more.”

Comment : This complies with the 2016 Rome IV diagnostic criteria for “functional diarrhea” [13] as well as the diagnostic criteria in the chronic diarrhea treatment guidelines announced by the British Gastroenterological Association in 2018 [8] and AGA in 2019 [17]. The duration of 4 weeks or more is set to rule out the possibility of infection-associated diarrhea. Stool form was defined using the BSFS because it is necessary to understand abnormal stool shape rather than frequency when assessing diarrhea. These guidelines exclude chronic diarrhea cases resulting from other causes, such as organic diseases. Chronic diarrhea is the cardinal symptom if soft or watery stools account for 25% or more of bowel movements. A diagnosis of chronic diarrhea in the narrow sense will be made, regardless of whether abdominal pain is present (this mainly indicates functional diarrhea, but in daily clinical practice, the chronic period is 4 weeks or more). Chronic diarrhea (narrow sense) does not explicitly include IBS-D. However, it does include patients who have not yet been definitively diagnosed with IBS-D and patients with IBS-D who have transitioned to mainly diarrhea in the course of their disease (Table 1).

Diagnostic criteria for chronic diarrhea

FRQ1-1. How is refractory chronic diarrhea defined?

There are no studies that have strictly defined refractory chronic diarrhea, making this a topic for future investigation.

Comment : Cases that do not respond to common diarrheal treatments and chronic diarrhea that recurs despite adequate treatment are thought to fall under the “refractory chronic diarrhea” category, but no studies have defined this term. In real-world clinical practice, attention must be paid to the fact that not only disease activity but also patient factors (comorbidities, treatment preferences, economic factors, regional characteristics, etc.) and medical provider factors (lack of knowledge and experience, biased drug selection, lack of patient communication) are associated with treatment resistance [20 , 21]. In the future, we hope to study the factors related to the severity and refractoriness of functional diarrhea.

FRQ2-1. What medical questionnaires are useful in chronic diarrhea treatment?

Currently, no specialized medical questionnaires for chronic diarrhea have been established to be useful in Japan.

Comment : Many questionnaires have been devised to evaluate diarrheal symptoms, but most of them have been designed to assess the effects of IBS-D on quality of life [22] and secondary diarrhea caused by other diseases such as acute enterocolitis, antibiotics, or anticancer drug treatment [23]. Although diarrheal symptoms are evaluated as a component of questionnaires for general functional gastrointestinal disorders in such questionnaires, there was only one questionnaire in this study that specifically evaluated diarrheal symptoms [24]. In the future, we expect new Japanese questionnaires to be created or those prepared overseas to be translated and their validity evaluated for improving the quality of treatment for chronic diarrhea.

BQ2-1. What physical examinations are useful in clinical management of chronic diarrhea?

In clinical management of chronic diarrhea, it is essential to discern the primary disease, so useful physical examinations include general condition/skin examination, craniocervical examination, abdominal/anal examination, and stool observation.

Comment : Although studies on the usefulness of specific physical examinations in the clinical management of chronic diarrhea are few, and currently, it is difficult to make an evaluation based on sufficient evidence, in daily clinical practice, it is nevertheless important to pay attention to physical findings in addition to abdominal symptoms, as this leads physicians to select and perform appropriate tests for differential diagnosis from a wide range of test items [25]. It is reported to be useful in classifying diarrhea and narrowing down a diagnosis before testing because the primary diseases causing chronic diarrhea are diverse and wide-ranging [26]. We suggest including a physical examination, and a medical interview when examining patients for chronic diarrhea is important.

CQ2-1. What are the warning symptoms and indications of chronic diarrhea? Also, are the warning symptoms and indications effective?

Warning symptoms and indications of chronic diarrhea include unexpected weight loss, nocturnal diarrhea, recent use of antibiotics, bloody stools, frequent or profuse diarrhea, undernutrition, and a family history of inflammatory bowel disease or colorectal cancer. However, their usefulness is unclear.

Comment : If the above warning symptoms and indications are observed in a patient with chronic diarrhea, further testing is required, but even if they are not observed, it is important to proceed with the treatment of chronic diarrhea by conducting a detailed medical history focused on diarrhea symptoms, physical examination, and minimal tests [1]. In other words, although checking for warning symptoms and indications to differentiate organic disease-associated diarrhea from chronic diarrhea (narrow sense) has been proposed, the usefulness of these warning symptoms and indications is not clear, and future research is needed [27].

CQ2-2. What laboratory tests (other than endoscopy) are useful in the differential diagnosis of chronic diarrhea?

There are blood, fecal, and imaging tests; the underlying disease and pathophysiology are examined from the interview and physical examination, and necessary tests are determined and carried out individually. (Strong recommendation, Evidence level A, 90% agreed)

Comment : Blood tests measure complete blood count, electrolytes, C-reactive protein, ALB, and urea nitrogen [8]. Malabsorption syndrome is likely to cause anemia, hypoproteinemia, and hypolipidemia because of iron, VB12, and folic acid deficiencies. Thyroid function tests (free T3, free T4, TSH) should be performed to differentiate hyperthyroidism. Consider the differential

diagnosis of *Clostridioides difficile* infection in patients with a history of antibiotic use, stool culture in patients suspected of bacterial enterocolitis, fecal egg testing, and direct microscopic examination for parasitosis [18]. Fecal occult blood testing is used to screen for neoplastic diseases in older people and IBD in young people. Fecal calprotectin (and lactoferrin) are elevated in IBD and are useful in differentiating it from IBS [28]. Abdominal CT tests (and MRI tests) are used to identify intestinal lesions in inflammatory and neoplastic diseases and to diagnose the presence of extraintestinal lesions such as exocrine pancreatic insufficiency and neuroendocrine tumors associated with pancreatic diseases [8]. However, these tests show no abnormalities for bile acid diarrhea and small intestinal bacterial overgrowth, so specific tests are required [8 , 29 , 30].

CQ2-3. What is the significance of endoscopy in the differential diagnosis of chronic diarrhea?

Colonoscopy is recommended for chronic diarrhea because it is useful in differential diagnosis and helps exclude organic diseases.

We recommend performing random biopsies even if no endoscopic abnormalities are found, to account for potential risks.

Comment : Colonoscopy for chronic diarrhea is useful in diagnosing and excluding organic diseases [1]. Given that endoscopy and random biopsies have been reported to show abnormal findings in 17–28% of patients with chronic diarrhea who meet Rome IV criteria [31], it is recommended to be performed particularly in empiric therapy-resistant cases, patients over the age of 50, and patients with warning indications [1 , 13]. Furthermore, to exclude diseases that require biopsy for diagnosis, such as microscopic colitis (lymphocytic colitis, collagenous colitis), eosinophilic gastroenteritis, and amyloidosis, it is recommended that random biopsies should be taken throughout the large intestine, to account for potential risk of biopsy [32].

CQ3-1. What is the prevalence of chronic diarrhea (narrow sense)?

The prevalence of chronic diarrhea (narrow sense) among Japanese people is estimated to be around 3–5%, and it tends to be more common among men.

Comment : Past studies have shown the prevalence of chronic diarrhea that lasts for more than 4 weeks to be 1.0–6.6%, with an etiology more diverse than that of acute diarrhea [8 , 33 , 34]. In Europe and America, the prevalence of chronic diarrhea has been reported at 4–5% [35]. As defined in these guidelines, chronic diarrhea mostly corresponds to the Rome IV criteria for functional diarrhea. An internet survey using the Rome IV criteria conducted in 33 countries worldwide found the prevalence of functional diarrhea to be 4.7%, while in Japan, and it was 5.2% [2]. However, there is little evidence for research on chronic diarrhea, making it difficult to evaluate because it varies depending on the definition and subject.

CQ3-2. Does chronic diarrhea (narrow sense) reduce QOL?

Chronic diarrhea (narrow sense) may reduce QOL and labor productivity.

Comment : Compared to patients with IBS-D, patients with functional diarrhea have been reported to complain of anxiety, depressive symptoms, and sleep disturbances, even though their abdominal pain and diarrhea are less severe [36]. A study comparing IBS patients with the general population of the USA showed that IBS patients had a lower QOL [37], and a study by Kanazawa et al. [38] in Japan also showed that IBS patients' QOL was lower than that of healthy subjects. It has also been shown that the labor productivity of people with chronic diarrhea declines significantly, with an annual economic loss upwards of USD 136 million [34]. These results suggest that chronic diarrhea reduces QOL and labor productivity, but studies from Japan are limited and based on little evidence.

FRQ3-1. Does chronic diarrhea (narrow sense) affect long-term prognosis?

Although no clear evidence that chronic diarrhea (narrow sense) affects long-term prognosis has been found, the details are unclear because the literature is insufficient.

Comment : Studies discussing the effects of chronic diarrhea (narrow sense) on long-term prognosis are few, and in Japan, there have been no investigations of long-term prognosis related to chronic diarrhea (narrow sense). Many cases of chronic diarrhea (narrow sense) have a good prognosis and are medically treatable, and there is no clear evidence that chronic diarrhea leads to death. However, a meta-analysis evaluating the long-term course of hemolytic uremic syndrome associated with diarrheal symptoms (mostly acute diarrhea, but including some chronic diarrhea) confirmed that approximately 12% of patients died [39], but this was a study of the long-term prognosis and acute diarrhea, with evidence for chronic diarrhea (narrow sense) expected to accumulate in the future.

FRQ4-1. What is the pathophysiology that causes chronic diarrhea (narrow sense)?

Though studies on chronic diarrhea (narrow sense) are few, various pathophysiologies have been proposed for IBS-D, which is considered to be on a continuous spectrum.

Comment : Mechanisms that cause diarrhea in IBS-D include: abnormalities in water absorption mechanisms [40 , 41]; microinflammation in the digestive tract [42 – 44]; mucosal barrier dysfunction [45]; abnormalities in hormones, amines, and peptides [46 – 49]; malabsorption of bile acid [30]; abnormalities in short-chain fatty acids [50]; intestinal motility disorders [51]; malabsorption of dietary components [52]; abnormalities of the autonomic nervous system [53]; genetic factors [54 , 55]; psychological abnormalities (FRQ4-02), lifestyle habits (CQ4-01), and intestinal bacteria abnormalities (FRQ4-03) (Table 2). Meanwhile, there are few reports of chronic diarrhea, and the pathophysiology is unclear.

Proposed mechanisms underlying diarrhea-predominant IBS and chronic diarrhea (narrow sense)

FRQ4-2. Do psychological abnormalities contribute to the pathophysiology of chronic diarrhea (narrow sense)?

There is no clear evidence showing a relationship between psychological abnormalities and the pathophysiology of chronic diarrhea (narrow sense).

Comment : There are many reports that psychological abnormalities are involved in the pathophysiology of IBS. Studies have shown that depression and anxiety are risk factors for the onset of IBS [111 , 112], that the prevalence of bipolar disorder is high in IBS patients [113], and that IBS is often accompanied by sleep disorders [114]. However, no direct reports on the relationship between psychological abnormalities and patients with only IBS-D are lacking. In contrast, no reports indicate a relationship between chronic diarrhea in the narrow sense (mainly functional diarrhea) and psychological abnormalities, and there is currently no evidence of a relationship between the two.

CQ4-1. Do lifestyle habits play a role in the pathophysiology of chronic diarrhea (narrow sense)?

Dietary content contributes to the pathophysiology of chronic diarrhea (narrow sense).

It is unclear whether lifestyle habits other than diet are involved in the pathophysiology of chronic diarrhea (narrow sense).

Comment : Excessive consumption of beverages containing fructose, caffeine, or foods containing xylitol may worsen diarrhea [115]. Fermentable oligosaccharides, disaccharides, monosaccharides, and polyols, which are difficult to digest and absorb in the small intestine, ferment in the large intestine to produce gas. Additionally, the osmotic concentration gradient increases the water in the small intestine, stimulating the intestinal tract to expand and causing pain, diarrhea, and loose stool symptoms because of intestinal overhydration. A low Fermentable oligosaccharides, disaccharides, monosaccharides, and polyols diet has been reported to improve symptoms of IBS-D [116]. While irregular eating habits and lack of exercise may be associated with symptoms of functional diarrhea [117], the association with smoking and alcohol consumption varies between studies, requiring further investigation.

FRQ4-3. Are intestinal bacteria involved in the pathophysiology of chronic diarrhea (narrow sense)?

There is a possibility that the intestinal bacteria are involved in the pathophysiology of chronic diarrhea (narrow sense).

Comment : A significant decrease in *Eubacterium rectale* , *Bacteroides* , *Faecalibacterium prausnitzii* , the main indigenous bacteria in stool, was observed in patients with chronic diarrhea as compared to healthy people, as was an increase in the relatively scarce indigenous bacteria *Bifidobacterium* , *Eubacterium cylindroides* , *Clostridium histolyticum* , and *Clostridium lituseburense* [118]. A systematic review of intestinal bacteria in IBS patients showed significant declines in the *Bifidobacterium* and *Faecalibacterium* genera in IBS-D patients compared to healthy subjects [119]. Whether these changes in the gut microbiome are a cause or a consequence of diarrhea is not fully understood, and further research is required. Given that probiotics and fecal transplantation may be effective against IBS symptoms [120 , 121], it is plausible that abnormal intestinal flora may cause chronic diarrhea.

FRQ5-1. Is lifestyle modification effective for chronic diarrhea (narrow sense)?

Although there is little evidence to support this, lifestyle modification may be effective for chronic diarrhea (narrow sense).

Comment : No studies have examined whether lifestyle modification is effective for chronic diarrhea (narrow sense). However, research has been conducted on whether lifestyle habits contribute to the pathophysiology, with studies showing that chronic diarrhea is associated with increased daily carbohydrate intake [122], lack of exercise on holidays, and irregular eating habits [117]. Although there is little evidence demonstrating the effectiveness of lifestyle modification for chronic diarrhea, we recommend that it be undertaken with the understanding that the evidence is uncertain but that implementing it has no disadvantage.

CQ5-1. Are probiotics effective for chronic diarrhea (narrow sense)?

Probiotics may be effective for chronic diarrhea (narrow sense). However, there is no clear evidence regarding the effective bacterial species, dosage, or duration of administration.

Comment : Often sold as supplements or pharmaceuticals, “probiotics” refer to live bacteria that benefit humans by improving the balance of intestinal bacteria, drugs, or foods containing those microorganisms. The clinical effectiveness of probiotics has been reported in the treatment of IBS-D, antibiotic-associated diarrhea, intestinal infections, and chemoradiotherapy-induced diarrhea [123]. Although not highly recommended in the British guidelines, as a treatment for IBS in particular, the validity of probiotics has been shown because of their effectiveness in improving symptoms and the low incidence of adverse events [124], and they are also highly recommended in clinical guidelines for IBS 2020 from the Japan Society of Gastroenterology [125]. Although probiotics’ symptom improvement and anti-inflammatory effects on chronic diarrhea have recently been reported [126], details on what mechanisms and which bacterial species are effective remain

subjects for further investigation.

CQ5-2. Are antidiarrheal drugs effective for chronic diarrhea (narrow sense)?

Loperamide hydrochloride is the most commonly used and effective drug for relieving symptoms of chronic diarrhea (narrow sense).

Comment : Loperamide hydrochloride is the most commonly used antidiarrheal drug in clinical practice, and it has been shown to control stool consistency in patients with chronic diarrhea [127], while loperamide oxide has been shown to reduce the weight of moist stool and improve patient symptoms [128]. Additionally, loperamide hydrochloride is effective in alleviating symptoms such as bile acid diarrhea [129], chronic radiation enteritis characterized primarily by diarrhea symptoms [130], and chemoradiotherapy-induced diarrhea [131]. These findings show that the administration of loperamide hydrochloride is effective as a first-choice for alleviating symptoms of chronic diarrhea.

FRQ5-2. Are serotonin (5-HT₃) receptor antagonists effective for chronic diarrhea (narrow sense)?

There is no evidence regarding the effect of 5-HT₃ receptor antagonists on chronic diarrhea (narrow sense). The effectiveness of 5-HT₃ receptor antagonists for chronic diarrhea (narrow sense) is unclear.

Comment : There is little evidence supporting the involvement of 5-HT₃ in the pathophysiology of patients with chronic diarrhea (narrow sense), and there are no reports examining the efficacy of 5-HT₃ receptor antagonists. However, 5-HT₃ receptor antagonists have been reported to alleviate abdominal pain and discomfort in IBS-D and improve defecation urgency, frequency, and stool form [132 , 133]. Functional diarrhea and IBS-D are considered to be on a continuum of pathological conditions with different phenotypes [19 , 36]. As with IBS-D patients, while 5-HT₃ receptor antagonists may be effective for some chronic diarrhea (narrow sense) patients, large-scale clinical studies are required to evaluate their validity and effectiveness.

FRQ5-3. Are anticholinergic drugs effective for chronic diarrhea (narrow sense)?

There is no evidence regarding the effects of anticholinergic drugs on chronic diarrhea (narrow sense). The effectiveness of anticholinergic drugs for chronic diarrhea (narrow sense) is unknown.

Comment : There is little or no research on the effectiveness of anticholinergic drugs for chronic diarrhea (narrow sense). Although there are relatively many studies on the effectiveness of anticholinergic drugs for IBS, data showing their effects on diarrheal symptoms is extremely limited. Though a meta-analysis showed that otilonium bromide effectively improves global symptoms in IBS patients, its effect on diarrheal symptoms is unclear [134]. In addition, the results of two RCTs on otilonium bromide were inconsistent regarding its effects on diarrheal symptoms in IBS patients [135 , 136]. Cimetropium bromide reduced the severity score of diarrheal symptoms in IBS by approximately 50%, but no statistically significant difference was observed compared with placebo [137].

FRQ5-4. Is Kampo medicine effective for chronic diarrhea (in a narrow sense)?

The effectiveness of Kampo medicines for chronic diarrhea (narrow sense) is unknown.

Comment : The elixir called “keishi-ka-shakuyaku-to” has analgesic and antispasmodic effects, suppresses intestinal spasms, and improves defecation symptoms, including abdominal pain and diarrhea. Additionally, the known pharmacological effects of the elixir “hange-shashin-to” include increasing water absorption in the large intestine and inhibiting intestinal peristalsis, which improves diarrheal symptoms. It is possible that Kampo medicines, because of their mechanism of action, are

effective against chronic diarrhea (narrow sense). However, the evidence level is insufficient, and further investigation is required.

FRQ5-5. Is psychotherapy effective for chronic diarrhea (narrow sense)?

The efficacy of psychotherapy for chronic diarrhea (narrow sense) is unknown.

Comment : There are no reports of studies in which psychotherapy was implemented for chronic diarrhea (narrow sense) [19]. It has been reported that acute stress accelerates transit through the digestive tract [138], but the relationship between chronic stress and functional diarrhea is unclear [19]. Further, since the psychological characteristics of functional diarrhea are not thought to be involved in the same way as those of IBS-D, psychotherapy for chronic diarrhea (narrow sense) cannot be expected to be as useful as for IBS, and therefore is thought to be limited. While there are no reports examining the effects of psychotherapy on chronic diarrhea (narrow sense) in detail, functional diarrhea, an academic diagnosis of chronic diarrhea (narrow sense), and IBS-D, though academically diagnosed differentially, are thought to be pathophysiologies on a continuum with different phenotypes. Therefore, there may be cases where psychotherapy has been effectively used to treat chronic diarrhea (narrow sense) and require further investigation.

FRQ5-6. Are antibiotics effective for chronic diarrhea (narrow sense)?

The efficacy of antibiotics for chronic diarrhea (narrow sense) is unknown.

Comment : There are no reports of studies examining the effects of antibiotics on chronic diarrhea (narrow sense) [19]. Clinical guidelines for functional bowel disorders with diarrhea as the main symptom, jointly published by the European Society of Gastrointestinal Endoscopy and the European Society of Neurogastroenterology and Motility, recommend the use of rifaximin, a nonabsorbable antibiotic, in IBS-D. However, the additional effect compared to placebo was not large, and there was little evidence of its effectiveness against functional diarrhea, an academic diagnosis of chronic diarrhea (narrow sense) [139].

Functional diarrhea and IBS-D are regarded as continuous pathophysiological conditions with different phenotypes, meaning they can transition from one into the other depending on the time, even in the same case, so while there are likely cases where antibiotics were effective against chronic diarrhea (narrow sense), this remains a topic for future investigation.

FRQ5-7. Are bulking agents effective for chronic diarrhea (narrow sense)?

The efficacy of bulking agents for chronic diarrhea (narrow sense) is unknown.

Comment : One bulking agent is calcium polycarbophil, a macromolecular polymer. It is not absorbed by the gastrointestinal tract; instead, it swells and forms a gel as it absorbs water in the intestines and is then excreted. Currently, no reports demonstrate the usefulness of calcium polycarbophil for functional diarrhea, which is an academic diagnosis for chronic diarrhea (in a narrow sense). Calcium polycarbophil is useful for IBS in a randomized controlled overseas trial [140]. Functional diarrhea and IBS-D are considered to be continuous pathophysiological conditions with different phenotypes, meaning they can transition from one into the other depending on the time, even in the same case, so there may be cases in which bulking agents are effective against functional diarrhea. However, because of insufficient evidence, no conclusions can be drawn now.

FRQ5-8. Are adrenergic agonists effective for chronic diarrhea (narrow sense)?

The effectiveness of adrenergic agonists for patients with chronic diarrhea (in a narrow sense) is unknown.

Comment : No evidence has been reported to recommend adrenergic agonists in patients with chronic diarrhea (narrow sense). In animal experiments, it has been reported to be effective in improving diarrhea [141]. In a placebo-controlled study in healthy subjects, α_2 -receptor agonist clonidine effectively increased colonic compliance, reduced sensations of tightness and abdominal gas, pain, and rectal urgency, and prolonged intestinal transit time [142]. Additionally, administering clonidine to patients with IBS-D was shown to improve their symptoms [143].

FRQ5-9. Are somatostatin analogs effective for chronic diarrhea (narrow sense)?

Somatostatin analogs may effective for chronic diarrhea (narrow sense). However, the evidence is limited, indicating a need for future investigation.

Comment : Somatostatin analogs inhibit intestinal motility and water-electrolyte transport [141 , 144]. Although few trials have examined their effects on chronic diarrhea (narrow sense), a Belgian prospective trial that tested lanreotide acetate showed improvement in 42.4% of patients [145]. Many trials have been conducted broadly for chronic diarrhea, and meta-analyses have shown the effectiveness of somatostatin analogs. However, caution is needed as the efficacy varies depending on the target disease [146 , 147]. Somatostatin analogs including octreotide acetate, lanreotide acetate, and pasireotide pamoate are approved for acromegaly, neuroendocrine tumors, but not for chronic diarrhea in Japan. Somatostatin analogs may be effective against chronic diarrhea (narrow sense), but the evidence is insufficient.

Based on the 10 CQs, 15 FRQs, and 2 BQs outlined in the guideline, we have constructed the flowcharts for clinical practice in managing chronic diarrhea. The first flowchart includes the initial medical treatment strategy of chronic diarrhea (Fig. 1). Initially, the patients with chronic diarrhea are assessed through medical interviews, physical findings, blood tests. Drug-induced diarrhea and food-induced diarrhea are differentiated. Subsequent studies including stool examinations, computed tomography, colonoscopy, and esophagogastroduodenoscopy are conducted to rule out systemic disease-associated diarrhea, infection-associated diarrhea, organic disease-associated diarrhea. Bile acid diarrhea is then excluded. The remaining patients are likely diagnosed with functional diarrhea or diarrhea-predominant IBS. Second flowchart includes the medical treatment strategy for chronic diarrhea (narrow sense) (Fig. 2). Initially, improvement in lifestyle habits and continuation of dietary therapy are recommended. If these prove ineffective, probiotics and antidiarrheal medications are administered. Should these have a poor response, the possibility of secondary chronic diarrhea should be reconsidered. Once secondary chronic diarrhea is ruled out, treatment options include 5HT₃ receptor antagonists, anticholinergics, Kampo medicines, psychotherapy, antibiotics, bulking agents, adrenergic agonists, somatostatin analogs, although their efficacy may be unclear.

Initial medical treatment strategy for chronic diarrhea. First, the patients with chronic diarrhea are assessed through medical interviews, physical findings, blood tests. Drug-induced diarrhea and food-induced diarrhea are differentiated. Subsequent studies including stool examinations, computed tomography, colonoscopy, esophagogastroduodenoscopy were conducted to rule out systemic disease-associated diarrhea, infection-associated diarrhea, organic disease-associated diarrhea. Bile acid diarrhea is then excluded. The remaining patients are likely diagnosed with functional diarrhea or diarrhea-predominant IBS. This guideline defines chronic diarrhea in a narrow sense. IBS, irritable bowel syndrome.

Medical treatment strategy for chronic diarrhea (narrow sense) Initially, improvement in lifestyle habits and continuation of dietary therapy are recommended. If these prove ineffective, probiotics and antidiarrheal medications are administered. Should these have a poor response, the possibility of secondary chronic diarrhea should be reconsidered. Once secondary chronic diarrhea is ruled out, treatment options include 5HT₃ receptor antagonists, anticholinergics, Kampo medicines, psychotherapy, antibiotics, bulking agents, adrenergic agonists, somatostatin analogs, although their efficacy may be unclear.

The members of the Guidelines Committee who created and evaluated the Japanese Gastroenterological Association “Evidence-based clinical guidelines for chronic diarrhea 2023” are listed.

Chair: Eikichi Ihara (Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University). Vice-Chair: Noriaki Manabe (Division of Endoscopy and Ultrasonography, Department of Clinical Pathology and Laboratory Medicine, Kawasaki Medical School). Members: Hidenori Ohkubo (Department of Gastroenterology, Sagami Rinkan Hospital), Naotaka Ogasawara (Department of Gastroenterology, Aichi Medical University School of Medicine), Haruei Ogino (Department of Gastroenterology and Metabolism, Graduate School of Medical Sciences, Kyushu University), Kazuki Kakimoto (2nd Department of Internal Medicine, Osaka Medical and Pharmaceutical University), Motoyori Kanazawa (Department of Behavioral Medicine, Tohoku University Graduate School of Medicine), Hidejiro Kawahara (Department of Surgery, National Hospital Organization Nishisaitama-Chuo National Hospital), Chika Kusano (Department of Gastroenterology, Kitasato University School of Medicine), Shiko Kuribayashi (Department of Gastroenterology and Hepatology, Gunma University Graduate School of Medicine), Akinari Sawada (Department of Gastroenterology, Osaka Metropolitan University Graduate School of Medicine), Tomohisa Takagi (Molecular Gastroenterology and Hepatology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine), Shota Takano (Department of Colorectal Surgery, Coloproctology Center Takano Hospital), Toshihiko Tomita (Division of Gastroenterology, Department of Internal Medicine, Hyogo Medical University), Toshihiro Noake (Department of Surgery, Kurume Coloproctology Center), Mariko Hojo (Department of Gastroenterology, Juntendo University Faculty of Medicine), Ryota Hokari (Department of Internal Medicine, National Defense Medical College), Tatsuhiro Masaoka (Center for Endoscopy, Kawasaki Municipal Hospital), Tomohiko Machida (Department of Surgery, Saiseikai Hyogo Prefectural Hospital), Noboru Misawa (Department of Gastroenterology and Hepatology, Yokohama City University School of Medicine), Yoshiyuki Mishima (Department of Internal Medicine II, Shimane University Faculty of Medicine), Hiroshi Yajima (Yashio Hospital), Sayuri Yamamoto (Department of General Medicine and Gastroenterology, Aichi Medical University), and Hiroshi Yamawaki (Department of Gastroenterology, Nippon Medical School Tama Nagayama Hospital).

Members: Tatsuya Abe (Department of Proctology, Kunitomo Hospital), Yasumi Araki (Department of Surgery, Kurume Coloproctology Center), Kunio Kasugai (Department of Gastroenterology, Aichi Medical University School of Medicine), Takeshi Kamiya (Department of Medical Innovation, Nagoya City University Graduate School of Medical Sciences), Akira Torii (Torii Medical Clinic), Atsushi Nakajima (Department of Gastroenterology and Hepatology, Yokohama City University Graduate School of Medicine), Koji Nakada (Kawamura Hospital), Shin Fukudo (Department of Psychosomatic Medicine, Japanese Red Cross Ishinomaki Hospital), Yasuhiro Fujiwara (Department of Gastroenterology, Osaka Metropolitan University Graduate School of Medicine), and Hiroto Miwa (Kawanishi City Medical Center).

President: Akihito Nagahara (Department of Gastroenterology, Juntendo University Faculty of Medicine).

Past President: Kazuhide Higuchi (Osaka Medical and Pharmaceutical University).

Directors Responsible: Hiromi Kataoka (Department of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Sciences).

The authors thank Kamada Kazuhiro (Department of Gastroenterology, Matsushita Memorial Hospital), Yoshimasa Tanaka (Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University), and Hiroko Hosaka (Department of Gastroenterology and Hepatology Gunma University Graduate School of Medicine Gunma) for assistance with data collection, data analysis, and manuscript preparation. The authors also thank the Japan Medical Library Association for assistance with professional bibliographic search.

The following were the competing interests of guideline development committee members, guideline committee members, and guideline Evaluation Committee members. Any financial relationship with enterprises, businesses or academic institutions in the subject matter or materials discussed in the manuscript are as follows: (1) those from which the authors, the spouse, partner or immediate relatives of the authors have received individually any income, honoraria or any other type of remuneration; Otsuka Pharmaceutical Co., Ltd., Takeda Pharmaceutical Company, EA Pharma Co., Ltd., Sanwa Kagaku Kenkyusho Co., Ltd., AstraZeneca K. K., Olympus Corporation, JIMRO Co., Ltd., AbbVie GK, KYORIN Pharmaceutical Co., Ltd., Viatris Inc., Astellas Pharma Inc., Gilead Sciences, Inc., Mitsubishi Tanabe Pharma Corporation, Pfizer Japan Inc., Mochida Pharmaceutical Co., Ltd., Janssen Pharmaceutical K. K., Tsumura and Co., Towa Pharmaceutical Co., Ltd., Bristol-Myers Squibb K. K., Kowa Pharmaceutical Co., Ltd., Taisho Pharmaceutical Holdings Co., Ltd., Biofermin Pharmaceutical Co., Ltd., Mylan EPD G. K., Daiichi Sankyo Inc., Zeria Pharmaceutical Co., Ltd., and (2) those from which the authors have received research grant; AbbVie GK, GlaxoSmithKline K. K., Janssen Pharmaceutical K. K., EA Pharma Co., Ltd., Fujifilm Corporation, Mochida Pharmaceutical Co., Ltd., Aska Pharmaceutical Co., Ltd., Astellas Pharma Inc., Gilead Sciences, Inc., Biofermin Pharmaceutical Co., Ltd., Mylan EPD G. K., Tsumura and Co., Zespri International Limited, and (3) those from which the authors have received scholarship; Eisai Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Tobishima Kodomo Clinic, Takeda Pharmaceutical Company, Daiichi Sankyo Inc., AbbVie GK, Kyorin Pharmaceutical Co., Ltd., Mitsubishi Tanabe Pharma Corporation, Bristol-Myers Squibb K. K., EA Pharma Co., Ltd., Mochida Pharmaceutical Co., Ltd., Ono Pharmaceutical Co., Ltd., Taiho Pharmaceutical Co. Ltd., Chugai Pharmaceutical Co. Ltd., Eli Lilly Japan K. K., and (4) those from which the authors have received individually endowed chair; Ono Pharmaceutical Co., Ltd., Miyarisan Pharmaceutical Co., Ltd., Sanwa Kagaku Kenkyusho Co., Ltd., Otsuka Pharmaceutical Factory, Inc., Fujifilm Medical Co., Ltd., Terumo Corporation, FANCL Corporation, Ohga Pharmacy, Abbott Japan LLC, and Muta Hospital.

The members of the guidelines development group are relevant professionals from the JGA. The funding body per se did not influence the content of the guidelines.

Writing – original draft: Eikichi Ihara, Noriaki Manabe, Hidenori Ohkubo, Naotaka Ogasawara, Haruei Ogino, kazuki Kakimoto, Motoyori Kanazawa, Hidejiro Kawahara, Chika Kusano, Shiko Kuribayashi, Akinari Sawada, Tomohisa Takagi, Shota Takano, Toshihiko Tomita, Toshihiro Noake, Mariko Hojo, Ryota Hokari, Tatsuhiko Masaoka, Tomohiko Machida, Noboru Misawa, Yoshiyuki Mishima, Hiroshi Yajima, Sayuri Yamamoto, and Hiroshi Yamawaki. Writing – review and editing: Eikichi Ihara and Noriaki Manabe. Supervision: Tatsuya Abe, Yasumi Araki, Kunio Kasugai, Takeshi Kamiya, Akira Torii, Atsushi Nakajima, Koji Nakada, Shin Fukudo, Yasuhiro Fujiwara, Hiroto Miwa, Hiromi Kataoka, Akihito Nagahara, and Kazuhide Higuchi.